CDXC Stock Forecast 2025-2026
Distance to CDXC Price Targets
CDXC Price Momentum
10 Quality Stocks Worth Considering Now
Researching ChromaDex (CDXC) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CDXC and similar high-potential opportunities.
Latest CDXC Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, CDXC has a bullish consensus with a median price target of $8.10 (ranging from $5.00 to $12.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $6.76, the median forecast implies a 19.8% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 77.5% upside. Conversely, the most conservative target is provided by Raghuram Selvaraju at HC Wainwright & Co., suggesting a 26.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CDXC Analyst Ratings
CDXC Price Target Range
Latest CDXC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CDXC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 8, 2025 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Mar 31, 2025 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Mar 17, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $11.00 |
| Mar 10, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $11.00 |
| Mar 5, 2025 | Ladenburg Thalmann | Jeffrey Cohen | Buy | Maintains | $8.10 |
| Nov 6, 2024 | Roth MKM | Sean McGowan | Buy | Maintains | $8.00 |
| Nov 4, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $8.00 |
| Aug 9, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $6.00 |
| Jul 15, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $6.00 |
| Jun 12, 2024 | Roth MKM | Sean McGowan | Buy | Maintains | $6.00 |
| May 9, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $6.00 |
| Apr 9, 2024 | Roth MKM | Sean McGowan | Buy | Maintains | $6.00 |
| Mar 11, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $6.00 |
| Aug 10, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $5.00 |
| Jun 5, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $5.00 |
| Mar 13, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $5.00 |
| Feb 1, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $5.50 |
| Aug 29, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $5.50 |
| Aug 16, 2022 | Oppenheimer | Brian Nagel | Perform | Downgrade | $0.00 |
| Aug 11, 2022 | B. Riley Securities | Jeff Van Sinderen | Neutral | Downgrade | $2.40 |
ChromaDex Corp. (CDXC) Competitors
The following stocks are similar to ChromaDex based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ChromaDex Corp. (CDXC) Financial Data
ChromaDex Corp. has a market capitalization of $611.90M with a P/E ratio of 71.5x. The company generates $99.60M in trailing twelve-month revenue with a 8.6% profit margin.
Revenue growth is +37.4% quarter-over-quarter, while maintaining an operating margin of +24.4% and return on equity of +22.9%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
ChromaDex Corp. (CDXC) Business Model
About ChromaDex Corp.
Develops and markets science-based dietary supplements.
ChromaDex Corp. generates revenue through the production and commercialization of dietary supplements, particularly its flagship product, Tru Niagen. The company employs a research-driven approach, leveraging proprietary technology and partnerships with academic and clinical institutions to ensure product efficacy and compliance with regulatory standards.
Operating at the intersection of health, wellness, and biotechnology, ChromaDex Corp. addresses the growing consumer demand for evidence-based health solutions in the nutraceutical sector. Its focus on healthy aging and cellular health positions the company favorably within a rapidly evolving market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
104
CEO
Mr. Robert N. Fried
Country
United States
IPO Year
2008
Website
www.chromadex.comChromaDex Corp. (CDXC) Latest News & Analysis
Niagen Bioscience, Inc. (formerly ChromaDex Corp.) has changed its name and will trade under the new Nasdaq symbol "NAGE" starting March 19, 2025.
The name change to Niagen Bioscience and new Nasdaq symbol "NAGE" may influence investor perception, signaling a strategic shift towards a focus on healthy aging and potentially affecting stock performance.
ChromaDex Corp. (NASDAQ:CDXC) will change its name to Niagen Bioscience, Inc. and its ticker symbol to "NAGE" on March 19, 2025. Further updates will be provided.
ChromaDex's rebranding to Niagen Bioscience and new Nasdaq symbol may signal a strategic shift, potentially impacting market perception and investor sentiment around its focus on healthy aging.
ChromaDex Corp. (NASDAQ: CDXC) will participate in the 37th Annual ROTH Conference. CEO Rob Fried will join a panel on Longevity and Supplementation on March 17, 2023.
ChromaDex's participation in a prominent conference highlights its focus on healthy aging and NAD+ research, potentially increasing visibility and investor interest in its growth prospects.
ChromaDex Corporation reported a 37.41% revenue increase and $7.2 million net income, driven by Niagen sales, but faces supply chain and regulatory challenges affecting growth.
ChromaDex's strong revenue growth and profitability highlight its market potential, but execution risks and external challenges could affect future performance and investor confidence.
ChromaDex Corporation (NASDAQ:CDXC) will hold its Q4 2024 earnings conference call on March 4, 2025, at 4:30 PM ET with key executives and analysts participating.
The upcoming earnings call on March 4, 2025, provides key insights into ChromaDex's financial performance and strategic direction, influencing investor sentiment and stock valuation.
ChromaDex Corp. (NASDAQ:CDXC) reported Q4 2024 net sales of $29.1 million, with a 37% increase in Tru Niagen® sales. Gross margin improved to 62.5%, and G&A expenses decreased by $4.4 million.
ChromaDex's strong sales growth and improved margins indicate robust demand for Tru Niagen®, potentially enhancing investor confidence and driving stock performance.
Frequently Asked Questions About CDXC Stock
What is ChromaDex Corp.'s (CDXC) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, ChromaDex Corp. (CDXC) has a median price target of $8.10. The highest price target is $12.00 and the lowest is $5.00.
Is CDXC stock a good investment in 2025?
According to current analyst ratings, CDXC has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.76. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CDXC stock?
Wall Street analysts predict CDXC stock could reach $8.10 in the next 12 months. This represents a 19.8% increase from the current price of $6.76. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ChromaDex Corp.'s business model?
ChromaDex Corp. generates revenue through the production and commercialization of dietary supplements, particularly its flagship product, Tru Niagen. The company employs a research-driven approach, leveraging proprietary technology and partnerships with academic and clinical institutions to ensure product efficacy and compliance with regulatory standards.
What is the highest forecasted price for CDXC ChromaDex Corp.?
The highest price target for CDXC is $12.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 77.5% increase from the current price of $6.76.
What is the lowest forecasted price for CDXC ChromaDex Corp.?
The lowest price target for CDXC is $5.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a -26.0% decrease from the current price of $6.76.
What is the overall CDXC consensus from analysts for ChromaDex Corp.?
The overall analyst consensus for CDXC is bullish. Out of 6 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.10.
How accurate are CDXC stock price projections?
Stock price projections, including those for ChromaDex Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.